Is the Tenofovir Based Therapy Almighty for Previous Treatment Failure in Chronic Hepatitis B?

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2016 Jul 6

PMID 27377908

Authors

Hyung Joon Yim

Affiliations

Soon will be listed here.

References

Petersen J, Ratziu V, Buti M, Janssen H, Brown A, Lampertico P . Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2011; 56(3):520-6. DOI: 10.1016/j.jhep.2011.09.018. View

Marcellin P, Ahn S, Ma X, Caruntu F, Tak W, Elkashab M . Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. 2015; 150(1):134-144.e10. DOI: 10.1053/j.gastro.2015.09.043. View

Yim H, Hwang S . Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol. 2013; 19(3):195-209. PMC: 3796671. DOI: 10.3350/cmh.2013.19.3.195. View

Peters M, Hann Hw H, Martin P, Heathcote E, Buggisch P, Rubin R . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2003; 126(1):91-101. DOI: 10.1053/j.gastro.2003.10.051. View

Lee S, Park J, Kim D, Kim B, Kim S, Song K . Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. J Med Virol. 2015; 88(6):1027-34. DOI: 10.1002/jmv.24427. View

Park J, Park S . Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol. 2015; 21(3):242-8. PMC: 4612285. DOI: 10.3350/cmh.2015.21.3.242. View

Xu D, Wang X, Shen X, Gong G, Ren H, Guo L . Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013; 59(3):450-6. DOI: 10.1016/j.jhep.2013.05.003. View

Lim Y, Yoo B, Byun K, Kwon S, Kim Y, An J . Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2015; 65(6):1042-51. DOI: 10.1136/gutjnl-2014-308435. View

Lanford R, Guerra B, Chavez D, Giavedoni L, Hodara V, Brasky K . GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013; 144(7):1508-17, 1517.e1-10. PMC: 3691056. DOI: 10.1053/j.gastro.2013.02.003. View

10.

Kim B, Jung S, Kim E, Kim J, Park J, Sung S . Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. J Gastroenterol Hepatol. 2015; 30(10):1514-21. DOI: 10.1111/jgh.12993. View

11.

Park J, Kim C, Bae S, Jung K, Kim H, Yoon S . Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int. 2016; 36(8):1108-15. DOI: 10.1111/liv.13059. View

12.

Kitrinos K, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P . No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2013; 59(2):434-42. DOI: 10.1002/hep.26686. View

13.

Kim H, Cho J, Kim Y, Gwak G, Paik Y, Choi M . Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med. 2015; 30(1):32-41. PMC: 4293561. DOI: 10.3904/kjim.2015.30.1.32. View

14.

Lim Y, Byun K, Yoo B, Kwon S, Kim Y, An J . Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2015; 65(5):852-60. DOI: 10.1136/gutjnl-2014-308353. View

15.

Kim J, Ahn S, Ko S, Choe W, Kim K, Kwon S . The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy. Clin Mol Hepatol. 2016; 22(2):241-9. PMC: 4946405. DOI: 10.3350/cmh.2015.0053. View

16.

Yim H, Hussain M, Liu Y, Wong S, Fung S, Lok A . Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006; 44(3):703-12. DOI: 10.1002/hep.21290. View

17.

Rapti I, Dimou E, Mitsoula P, Hadziyannis S . Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007; 45(2):307-13. DOI: 10.1002/hep.21534. View

18.

Lim Y, Lee T, Heo N, Shim J, Lee H, Suh D . Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. Antivir Ther. 2012; 17(1):53-60. DOI: 10.3851/IMP1914. View

19.

Marcellin P, Heathcote E, Buti M, Gane E, de Man R, Krastev Z . Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23):2442-55. DOI: 10.1056/NEJMoa0802878. View

20.

Lee Y, Lee J, Lee D, Cho H, Ahn H, Choi W . Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014; 58(11):6710-6. PMC: 4249402. DOI: 10.1128/AAC.03845-14. View